ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Efficient Batch Record Design and Review Course: Master Batch Records (MBR), Regulatory Requirements, and Key Steps for Issuance, Batch Record Review, Reconciliation, and Final QA Disposition - ResearchAndMarkets.com

The "Efficient Batch Record Design and Review" training has been added to ResearchAndMarkets.com's offering.

This accredited training will identify and discuss Master Batch Records (MBR), regulatory requirements, and key steps for issuance, batch record review, reconciliation, and final QA disposition.

Regulatory Agencies require firms to have written procedures in place to document production and process controls, better known as batch records. Additionally, there must be written procedures for a batch record review process to demonstrate compliance. A strong batch record review system is essential to properly document all critical and operational process parameters that go along with the production and manufacture of pharmaceuticals, biologics, medical devices, etc.

Several examples and case studies of best practices will be demonstrated to emphasize how an effective batch record review is conducted based on current quality/regulatory requirements.

Who Should Attend:

This online training is designed for professionals in the Pharmaceutical, Medical Device, and other life science industries. This Education Course is designed for all persons in Production and Quality Units who deal with the design and review of batch documentation in pharmaceutical, biopharmaceutical and API production. It is also addressed to Qualified Persons who want to improve their system of the batch record review

It will be especially valuable to the personnel and management, including senior management, in these areas:

  • Quality Assurance
  • Quality Control
  • Facilities
  • Manufacturing
  • Validation Professions in GMPs and Pharmaceuticals

Key Topics Covered:

Regulatory Requirements Applying to Batch Record Review, Pharmaceutical Documentation & the Quality System

  • Global regulations and expectations
  • Regulations Update and Latest Developments in Industry
  • How documentation fits into the Quality System of recommendations and regulations
  • Important data for Quality Assurance
  • Risk Assessment and Continuous Improvement

The Design of the Master Batch Documentation

  • Is there a need for re-design?
  • Important aspects to consider
  • How to gain efficiency

Efficiency in Batch Record Review

  • Layout and handling
  • How to reduce review time: examples
  • How to handle and document deviations
  • How to present review results to the QP
  • Balanced Score Card
  • KPIs

Risk Assessment/ Management Applications within the Batch Record Process

  • How the risk lifecycle links with the BRR stages:
  • Risks associated with paper and electronic records
  • Risks associated with people checking documentation
  • Relative risk factors
  • Risks associated with the process
  • Risks for QP 'discretion'
  • Quality Risk Management
  • Impact the effectiveness of deviations, OOS

Change Controls

  • Improvement of root cause investigations
  • Using QRM to perform a SWOT analysis
  • What does a good risk assessment look like?

QA Oversight on EBR validation activities

  • Validation Life Cycle
  • Qualification activities
  • Maintenance
  • Training

Speakers:

Kelly Thomas

Vice President

Stallergenes Greer

Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.

Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.

For more information about this training visit https://www.researchandmarkets.com/r/ibx3wf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.18
-0.22 (-0.09%)
AAPL  272.65
+3.22 (1.20%)
AMD  239.62
-4.36 (-1.79%)
BAC  53.72
+0.30 (0.56%)
GOOG  289.28
-1.31 (-0.45%)
META  621.86
-9.90 (-1.57%)
MSFT  503.31
-2.69 (-0.53%)
NVDA  192.19
-6.86 (-3.45%)
ORCL  229.87
-10.97 (-4.55%)
TSLA  433.76
-11.47 (-2.58%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.